Windtree Therapeutics Inc (WINT)

Healthcare11/16/2023 6:45 PM

Go to Registration Page


Windtree Therapeutics, Inc. is advancing late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock. Windtree's heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree's portfolio is rostafuroxin, a novel precision drug product targeting the treatment resistant hypertension disease state for patients with certain genetic profiles.


Rate This Webinar

community rating (0 votes): 
Rate or Review This Webinar


Windtree Therapeutics

Windtree Therapeutics

A biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications.